CO7400871A2 - Heteroaryl substituted pyridyl compounds useful as kinase modulators - Google Patents

Heteroaryl substituted pyridyl compounds useful as kinase modulators

Info

Publication number
CO7400871A2
CO7400871A2 CO15127843A CO15127843A CO7400871A2 CO 7400871 A2 CO7400871 A2 CO 7400871A2 CO 15127843 A CO15127843 A CO 15127843A CO 15127843 A CO15127843 A CO 15127843A CO 7400871 A2 CO7400871 A2 CO 7400871A2
Authority
CO
Colombia
Prior art keywords
compounds useful
kinase modulators
heteroaryl substituted
substituted pyridyl
pyridyl compounds
Prior art date
Application number
CO15127843A
Other languages
Spanish (es)
Inventor
Rajeev S Bhide
John V Duncia
John Hynes
Satheesh K Nair
William J Pitts
Sreekantha R Kumar
Daniel S Gardner
Natesan Murugesan
Venkatram Reddy Paidi
Joseph B Santella
Ramesh Sistla
Hong Wu
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CO7400871A2 publication Critical patent/CO7400871A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos quetienen la siguiente Fórmula: o un estereoisómero o una sal de los mismosfarmacéuticamente aceptable, en donde R2 es un grupoheteroarilo monocíclico, y R1, R3, R4, R5 y R6 como se definenen la presente, son útiles como moduladores de cinasa, lo queincluye la inhibición de IRAK-4.The present invention relates to compounds having the following Formula: or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein R2 is a monocyclic heteroaryl group, and R1, R3, R4, R5 and R6 as defined herein, are useful as kinase modulators, which includes the inhibition of IRAK-4.

CO15127843A 2012-11-08 2015-06-03 Heteroaryl substituted pyridyl compounds useful as kinase modulators CO7400871A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261723848P 2012-11-08 2012-11-08
US201361774824P 2013-03-08 2013-03-08

Publications (1)

Publication Number Publication Date
CO7400871A2 true CO7400871A2 (en) 2015-09-30

Family

ID=49667571

Family Applications (1)

Application Number Title Priority Date Filing Date
CO15127843A CO7400871A2 (en) 2012-11-08 2015-06-03 Heteroaryl substituted pyridyl compounds useful as kinase modulators

Country Status (21)

Country Link
US (3) US9657009B2 (en)
EP (1) EP2917206B1 (en)
JP (1) JP6204484B2 (en)
KR (1) KR20150079963A (en)
CN (1) CN104781254B (en)
AU (1) AU2013341200A1 (en)
BR (1) BR112015009850A2 (en)
CA (1) CA2890983A1 (en)
CL (1) CL2015001249A1 (en)
CO (1) CO7400871A2 (en)
EA (1) EA024940B1 (en)
ES (1) ES2615302T3 (en)
HK (1) HK1213895A1 (en)
IL (1) IL238609A0 (en)
MX (1) MX2015005562A (en)
PE (1) PE20150953A1 (en)
PH (1) PH12015501005A1 (en)
SG (1) SG11201503397YA (en)
TN (1) TN2015000175A1 (en)
TW (1) TW201427953A (en)
WO (1) WO2014074675A1 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6215338B2 (en) 2012-11-08 2017-10-18 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Bicyclic heterocycle-substituted pyridyl compounds useful as kinase modulators
EA024940B1 (en) 2012-11-08 2016-11-30 Бристол-Майерс Сквибб Компани Heteroaryl substituted pyridyl compounds useful as kinase modulators
SG11201504857SA (en) 2012-12-21 2015-07-30 Gilead Sciences Inc Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
NO2865735T3 (en) 2013-07-12 2018-07-21
AR098991A1 (en) * 2014-01-03 2016-06-22 Bristol Myers Squibb Co NICOTINAMIDE COMPOUNDS REPLACED WITH HETEROARILE
TWI677489B (en) * 2014-06-20 2019-11-21 美商基利科學股份有限公司 Synthesis of polycyclic-carbamoylpyridone compounds
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (en) 2014-06-20 2018-06-23
TW201713655A (en) 2015-06-24 2017-04-16 必治妥美雅史谷比公司 Heteroaryl substituted aminopyridine compounds
TW201718571A (en) 2015-06-24 2017-06-01 必治妥美雅史谷比公司 Heteroaryl substituted aminopyridine compounds
TW201713663A (en) * 2015-06-24 2017-04-16 必治妥美雅史谷比公司 Heteroaryl substituted aminopyridine compounds
TWI724022B (en) 2015-09-02 2021-04-11 英商葛蘭素史密斯克藍智慧財產權有限公司 Compounds
WO2017050714A1 (en) 2015-09-22 2017-03-30 Glaxosmithkline Intellectual Property (No.2) Limited Pyridinone dicarboxamide for use as bromodomain inhibitors
KR20180059551A (en) 2015-10-05 2018-06-04 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 2-oxo-1,2-dihydropyridine-3,5-dicarboxamide compound as a bromo domain inhibitor
WO2017089985A1 (en) * 2015-11-26 2017-06-01 Novartis Ag Diamino pyridine derivatives
AU2017245641A1 (en) 2016-04-07 2018-09-13 Glaxosmithkline Intellectual Property (No.2) Limited Pyridyl derivatives as bromodomain inhibitors
JP6885968B2 (en) * 2016-05-24 2021-06-16 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ Pyridine dicarboxamide derivative as a bromodomain inhibitor
JOP20180011A1 (en) 2017-02-16 2019-01-30 Gilead Sciences Inc PYRROLO[1,2-b] PYRIDAZINE DERIVATIVES
GB201703282D0 (en) 2017-03-01 2017-04-12 Glaxosmithkline Intellectual Property (No 2) Ltd Compounds
JOP20190192A1 (en) 2017-03-01 2019-08-08 Glaxosmithkline Ip No 2 Ltd Pyrazole derivatives as bromodomain inhibitors
EA039189B1 (en) 2017-05-11 2021-12-15 Бристол-Маерс Сквибб Компани Thienopyridines and benzothiophenes as irak4 inhibitors
EP3642204A1 (en) 2017-06-21 2020-04-29 H. Hoffnabb-La Roche Ag PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
JP2020524663A (en) 2017-06-21 2020-08-20 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Isoindolinone derivatives as IRAK4 modulators
US11358948B2 (en) 2017-09-22 2022-06-14 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
IL295603B2 (en) 2017-09-22 2024-03-01 Kymera Therapeutics Inc Protein degraders and uses thereof
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
IL275649B2 (en) 2017-12-26 2023-12-01 Kymera Therapeutics Inc Irak degraders and uses thereof
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
EP3737675A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
EP3817748A4 (en) 2018-07-06 2022-08-24 Kymera Therapeutics, Inc. Tricyclic crbn ligands and uses thereof
TWI721483B (en) 2018-07-13 2021-03-11 美商基利科學股份有限公司 Pyrrolo[1,2-b]pyridazine derivatives
WO2020051571A1 (en) * 2018-09-07 2020-03-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Brd4-jak2 inhibitors
WO2020051572A1 (en) * 2018-09-07 2020-03-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Brd4-jak2 inhibitors
CN113423427A (en) 2018-11-30 2021-09-21 凯麦拉医疗公司 IRAK degrading agents and uses thereof
CN114174304B (en) * 2019-07-23 2024-05-17 百时美施贵宝公司 Thienopyridinyl and thiazolopyridinyl compounds useful as IRAK4 inhibitors
WO2021127283A2 (en) 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Irak degraders and uses thereof
IL293917A (en) 2019-12-17 2022-08-01 Kymera Therapeutics Inc Irak degraders and uses thereof
UY39002A (en) 2019-12-23 2021-07-30 Blueprint Medicines Corp EGFR INHIBITORS
TW202210483A (en) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Crystalline forms of irak degraders
US20240076285A1 (en) * 2020-12-16 2024-03-07 Shankar Venkatraman Compounds and compositions for treating conditions associated with sting activity
WO2023092034A1 (en) * 2021-11-17 2023-05-25 Northwestern University Wt-idh1 inhibition using a covalent and brain-penetrant small molecular inhibitor for ferroptosis induction in high-grade glioma

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2450769A1 (en) 2001-06-15 2002-12-27 Vertex Pharmaceuticals Incorporated 5-(2-aminopyrimidin-4-yl) benzisoxazoles as protein kinase inhibitors
AUPR688101A0 (en) 2001-08-08 2001-08-30 Luminis Pty Limited Protein domains and their ligands
GB0211019D0 (en) 2002-05-14 2002-06-26 Syngenta Ltd Novel compounds
US7449456B2 (en) 2002-06-28 2008-11-11 Astellas Pharma, Inc. Diaminopyrimidinecarboxamide derivative
MXPA05007503A (en) 2003-01-17 2005-09-21 Warner Lambert Co 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation.
CN1820001A (en) 2003-07-10 2006-08-16 神经能质公司 Substituted heterocyclic diarylamine analogues
GB0402653D0 (en) 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
FR2896503B1 (en) 2006-01-23 2012-07-13 Aventis Pharma Sa NOVEL CYCLIC UREA SULFUR DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE AS INHIBITORS OF KINASES
BRPI0809896A2 (en) 2007-06-08 2014-10-07 Bayer Cropscience Sa COMPOUND, FUNGICIDE COMPOSITION AND METHOD FOR CONTROL OF CROP PHYTOPATHOGENIC FUNGI
WO2009046416A1 (en) 2007-10-05 2009-04-09 Targegen Inc. Anilinopyrimidines as jak kinase inhibitors
GB0719644D0 (en) 2007-10-05 2007-11-14 Cancer Rec Tech Ltd Therapeutic compounds and their use
EP2070924A1 (en) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft New 2 hetarylthiazol-4-carboxylic acid derivatives, their manufacture and use as medicine
WO2010061971A1 (en) * 2008-11-28 2010-06-03 興和株式会社 Pyridine-3-carboxyamide derivative
EP2440204B1 (en) 2009-06-12 2013-12-18 Bristol-Myers Squibb Company Nicotinamide compounds useful as kinase modulators
BR112012010220A2 (en) 2009-10-30 2021-02-23 Janssen Pharmaceutical N.V. phenoxy-substituted pyridines as opioid receptor modules
CN102971304A (en) 2010-02-01 2013-03-13 日本化学医药株式会社 GPR119 agonist
US8518948B2 (en) 2010-03-10 2013-08-27 Ingenium Pharmaceuticals Gmbh Inhibitors of protein kinases
WO2012149567A1 (en) 2011-04-29 2012-11-01 Mount Sinai School Of Medicine Kinase inhibitors
EP2802579B1 (en) 2012-01-13 2016-04-13 Bristol-Myers Squibb Company Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors
JP6109195B2 (en) 2012-01-13 2017-04-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Heterocycle-substituted pyridyl compounds useful as kinase inhibitors
US8987311B2 (en) 2012-01-13 2015-03-24 Bristol-Myers Squibb Company Triazolyl-substituted pyridyl compounds useful as kinase inhibitors
US9315494B2 (en) * 2012-11-08 2016-04-19 Bristol-Myers Squibb Company Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNα responses
EA024940B1 (en) 2012-11-08 2016-11-30 Бристол-Майерс Сквибб Компани Heteroaryl substituted pyridyl compounds useful as kinase modulators
AR098991A1 (en) 2014-01-03 2016-06-22 Bristol Myers Squibb Co NICOTINAMIDE COMPOUNDS REPLACED WITH HETEROARILE

Also Published As

Publication number Publication date
JP6204484B2 (en) 2017-09-27
CN104781254A (en) 2015-07-15
SG11201503397YA (en) 2015-05-28
PE20150953A1 (en) 2015-06-20
MX2015005562A (en) 2015-07-23
EP2917206B1 (en) 2016-12-21
CA2890983A1 (en) 2014-05-15
BR112015009850A2 (en) 2017-07-11
US20150284382A1 (en) 2015-10-08
US10023562B2 (en) 2018-07-17
TW201427953A (en) 2014-07-16
CN104781254B (en) 2016-12-14
TN2015000175A1 (en) 2016-10-03
CL2015001249A1 (en) 2015-07-31
HK1213895A1 (en) 2016-07-15
IL238609A0 (en) 2015-06-30
JP2016501186A (en) 2016-01-18
ES2615302T3 (en) 2017-06-06
US9657009B2 (en) 2017-05-23
EA201590920A1 (en) 2015-09-30
US20180370956A1 (en) 2018-12-27
AU2013341200A1 (en) 2015-07-02
EA024940B1 (en) 2016-11-30
US10544133B2 (en) 2020-01-28
EP2917206A1 (en) 2015-09-16
KR20150079963A (en) 2015-07-08
US20170210730A1 (en) 2017-07-27
WO2014074675A1 (en) 2014-05-15
PH12015501005A1 (en) 2015-07-27

Similar Documents

Publication Publication Date Title
CO7400871A2 (en) Heteroaryl substituted pyridyl compounds useful as kinase modulators
CR20150418A (en) TETRAHYDROPIRROLOTIAZINE COMPOUNDS
EA201691085A1 (en) SUBSTITUTED BENZAMIDES AND METHODS OF THEIR APPLICATION
EA201690473A1 (en) COMBINED COMPOSITION OF TWO ANTI-VIRUS COMPOUNDS
UY35333A (en) AZABENCIMIDAZOL COMPOUNDS
EA201590296A1 (en) DEUTERATED IBRUTINIB
EA201590951A1 (en) DIHYDROPYRAZOL GPR40 MODULATORS
EA201490474A1 (en) AMINOHINAZOLINS AS KINAZ INHIBITORS
EA201590954A1 (en) DIHYDROPYRAZOL GPR40 MODULATORS
EA201690911A1 (en) COMPOUNDS OF DIMETHYLBENE ACID
EA201590949A1 (en) DIHYDROPYRAZOL GPR40 MODULATORS
DOP2014000287A (en) PIPERIDINE PHENOXIETIL COMPOUNDS
EA201690894A1 (en) PHENOXYETHYLES
EA201591815A1 (en) BICYCLO [2.2.2] ACIDS - GPR120 MODULATORS
DOP2014000250A (en) NEW PIRAZOL COMPOUNDS
EA201590552A1 (en) AMINOHINOLINES AS KINASE INHIBITORS
EA201592183A1 (en) BACE INHIBITORS
CR20170035A (en) IMIDAZOPIRIDAZINE COMPOUNDS
EA201590561A1 (en) PROCARE OF AMINOCHINAZOLINE KINASE INHIBITOR
AR095097A1 (en) PHENOXYETOXI COMPOUNDS
CR20140495A (en) 5-AMINO [1,4] THIAZINES AS INHIBITORS OF BACE1
PH12015502032A1 (en) Azetidinyloxyphenylpyrrolidine compounds
EA201591915A1 (en) COMPOUNDS OF PHENOXYETHYL DIHYDRO-1H-IZOHINOLINA
CR20150325A (en) TRICYCLE COMPOUNDS TO INHIBIT THE CFTR CHANNEL
EA201690924A1 (en) Fluorphenylpyrazole compounds